spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

E Ink and Faubel Unveil the Med Label to Revolutionize the Clinical Trial Supply Chain

Faubel & Co. Nachfolger GmbH

The Smart Label Simplifies and Shortens Expiry Updates Allowing for Considerable Time and Cost Savings


E Ink® Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology and Faubel & Co. Nachf. GmbH, a proven supplier to the pharmaceutical and chemical industry, announced the availability of the Faubel-Med® Label, a smart label for investigational medicinal products. The Med Label features E Ink’s low-voltage film technology, bringing display modules and new system designs to pharmaceutical packaging.

The Med Label is a combination of an ePaper display and a booklet label that is integrated with radio-frequency identification (RFID) technology to allow pharmaceutical packaging to be updated on demand. The Med Label features a segmented bi-stable E Ink display that can provide expiry updates - even on a sealed kit. This digital solution provides pharmaceutical companies an alternative to relabeling whenever stability data changes, allowing for considerable time and cost savings to international clinical trials.

“The Med Label is a breakthrough product that makes the handling of investigational medicinal products in clinical trial supply chains so much easier,” said Konrad Zachman, head of production for new technologies at Faubel. “As we see a continuous growth in biologic products that require frequent updates on stability data, the Med Label emerges as a cost-effective, highly-efficient smart label that meets the demands of present and future compliance requirements.”

Thanks to E Ink’s ePaper solution, Faubel is expanding its service offerings to provide connected labels with RFID and ePaper technology. Furthermore, this innovation enables the pharmaceutical industry to go digital using valuable tools such as software and real-time reporting, among others. “We believe this is a game changer that will transform clinical trials, saving the industry time and money”, said Frank Jäger, managing director at Faubel. The Med Label is equipped with a battery-free, always-on ePaper display and an RFID tag. It facilitates on-demand label updates for expiry dates at the clinical depot site and provides real time reporting and documentation that meet compliance requirements.

“E Ink’s smart packaging solutions are at the forefront of pharmaceutical packaging innovation,” said Paul Apen, Chief Strategy Officer at E Ink. “Adding displays to pharma packaging requires thin and flexible displays that are also low-power. Our ePaper displays are perfect for this application given their thin, low voltage properties, as well as easy readability, contrast and wide viewing angle.”

E Ink’s new low-voltage film uses roughly 5v compared to the typical 15v driving voltage for electronic paper displays, which decreases the power required for label updates and speeds the update process. “We are thrilled to partner with Faubel to create a product that will help the pharmaceutical industry take advantage of the digital resources at its disposal,” said FY Gan, Executive Vice President of Sales Center at E Ink. “The potential to enhance and simplify clinical trials is endless; we’re excited to collaborate with industry leaders like Faubel to provide system integration capability for not only the pharmaceutical industry in a total solution, but a wide range of smart packaging applications that deliver the best customer experience of using e-paper for digital transformation.”

About E Ink Holdings

E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media Lab, has transformed and defined the eReader market and is redefining the signage, architecture and design, mobile, wearable and retail markets with its ePaper technology, enabling a new multi-billion dollar market in less than 10 years. Its corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays. For more information please visit www.eink.com.

About Faubel:

The Faubel Group is a global supplier of functional labels with various locations in Europe, the USA and Asia. The Faubel Pharma Services business unit has positioned itself as an innovation and quality leader in clinical trial labeling for multinational trials. Faubel Pharma Services deals with label design, the production of labels of up to 113 pages, the overprinting of pre-produced bulk goods with variable data as well as with routing. In addition to these established services, the multi-service provider develops individual packaging concepts that are able to mask investigational medicinal products and to withstand temperatures down to -196°C. With its Faubel-Med® Label, the company offers a unique label whose contents can be updated digitally. When stability data changes, the Med Label replaces re-labeling and provides the necessary flexibility for study pooling.
phone +49 5661 7309-0
email info@faubel.de
web www.faubel.de
email Schwarzenberger Weg 45, 34212 Melsungen
 
Print this page
Send to a friend
   
spacer
News and Press Releases

PPMA Group Industry Awards 2018 Call for Entries – Deadline 31st July

The PPMA Group Industry Awards, which recognise manufacturing excellence, technical innovation, entrepreneurship as well as outstanding achievement and contribution to the industry, will this year take place at a new venue – the Hilton Birmingham Metropole Hotel at the NEC - on the 25th September 2018.
More info >>


White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

Industry Events

10th Annual NGS & Clinical Diagnostics Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 10thAnnual NGS & Clinical Diagnostics Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement